Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Winkelmann

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Current Pharmaceutical Design|May 23, 2012
Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous systemAlexander Winkelmann, Uwe K Zettl
Der Nervenarzt|September 19, 2019
[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation]Alexander Winkelmann, Micha Löbermann, Uwe K Zettl
MMW Fortschritte Der Medizin|June 8, 2015
[Autism and multiple sclerosis following measles vaccination: update on current knowledge]Alexander Winkelmann, M Löbermann, U K Zettl
Scientific Reports|September 2, 2023
Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort studyAlexander Winkelmann, Christoph Metze, Uwe K Zettl, et al.
Journal of Neurology|March 21, 2009
Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosisRobert Patejdl, Alexander Winkelmann, Reiner Benecke, et al.
Journal of Neurology|May 16, 2007
Cognitive impairment in multiple sclerosisAlexander Winkelmann, Claudia Engel, Annett Apel, et al.
CNS Neuroscience & Therapeutics|June 3, 2018
Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal periodAlexander Winkelmann, Paulus Stefan Rommer, Michael Hecker, et al.
Journal of Neurology|March 21, 2009
Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapyAlexander Winkelmann, Robert Patejdl, Sabine Wagner, et al.
Journal of Clinical Medicine|July 9, 2022
Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple SclerosisRüdiger Birke, Stefanie Meister, Alexander Winkelmann, et al.
CNS Drugs|June 25, 2011
Rituximab for secondary progressive multiple sclerosis: a case seriesPaulus S Rommer, Robert Patejdl, Alexander Winkelmann, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Current Pharmaceutical Design|May 23, 2012
Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous systemAlexander Winkelmann, Uwe K Zettl
Der Nervenarzt|September 19, 2019
[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation]Alexander Winkelmann, Micha Löbermann, Uwe K Zettl
MMW Fortschritte Der Medizin|June 8, 2015
[Autism and multiple sclerosis following measles vaccination: update on current knowledge]Alexander Winkelmann, M Löbermann, U K Zettl
Scientific Reports|September 2, 2023
Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort studyAlexander Winkelmann, Christoph Metze, Uwe K Zettl, et al.
Journal of Neurology|March 21, 2009
Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosisRobert Patejdl, Alexander Winkelmann, Reiner Benecke, et al.
Journal of Neurology|May 16, 2007
Cognitive impairment in multiple sclerosisAlexander Winkelmann, Claudia Engel, Annett Apel, et al.
CNS Neuroscience & Therapeutics|June 3, 2018
Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal periodAlexander Winkelmann, Paulus Stefan Rommer, Michael Hecker, et al.
Journal of Neurology|March 21, 2009
Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapyAlexander Winkelmann, Robert Patejdl, Sabine Wagner, et al.
Journal of Clinical Medicine|July 9, 2022
Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple SclerosisRüdiger Birke, Stefanie Meister, Alexander Winkelmann, et al.
CNS Drugs|June 25, 2011
Rituximab for secondary progressive multiple sclerosis: a case seriesPaulus S Rommer, Robert Patejdl, Alexander Winkelmann, et al.
Pageof 5